Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03145181 |
|---|---|
| Brief Title: | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) |
| First Submitted : | April 28, 2017 |
| First Submitted that Met QC Criteria : | May 8, 2017 |
| First Posted : | May 9, 2017 |
| Last Update Submitted that Met QC Criteria : | April 23, 2024 |
| Last Update Posted : | April 25, 2024 |